

[x](#)

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
 - For example, a search on Aminosalicic Acid Tablets will result in anything that contains “Aminosalicic” OR “Acid” OR “Tablets”
 - A search for “Aminosalicic Acid Tablets” will result in anything that specifically contains “Aminosalicic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
 - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MESO-	CHEMICAL	<i>USPNF Online</i> Online	27-Jan-2023	1-Jun-2023	NA	NA	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ZEAXANTHIN	INFORMATION							(3R,3'S-meso)-Zeaxanthin to: (3R,3'S)-Zeaxanthin
MAGNESIUM OXIDE	IM PURITIES/ <i>Limit of Calcium</i>	USPNF Online	Online	25-Feb-2022	1-Dec-2022	NA	NA	In <i>Analysis</i> : Change C_U = concentration of Magnesium Hydroxide in the <i>Sample solution</i> (mg/mL) to: C_U = concentration of Magnesium Oxide in the <i>Sample solution</i> (mg/mL)
MAFENIDE ACETATE FOR TOPICAL SOLUTION	IM PURITIES/ <i>Organic Impurities</i>	USPNF Online	Online	16-Dec-2022	1-Jan-2023	NA	NA	In <i>System suitability</i> : Change Samples : <i>System suitability solution</i> , <i>Standard solution A</i> , and <i>Standard</i>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<p><i>solution B</i> to: Samples: <i>System suitability solution and Standard solution A</i> AND In Analysis: Change Samples: <i>Mobile phase, Standard solution A, and Sample solution</i> Chromatograph the <i>Standard solution</i> and adjust the integration parameters so that the response is 5%–15% of full-scale deflection. to: Samples: <i>Mobile phase, Standard</i></p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LYSINE HYDR IM OCHLORIDE PUR ITIES/Related Compounds	USPNF Online	Online	16-Dec-2022	1-Jun-2023	NA	NA	<p><i>solution A, Standard solution B, and Sample solution Chromatograph Standard solution B and adjust the integration parameters so that the response is 5%–15% of full-scale deflection. In Chromatographic system/Spray reagent. Change 0.2 g of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5) to: 2 mg/mL of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid</i></p>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sort ascending								
LYSINE ACETATE	IM PURITIES/Related Compounds	USPNF Online	Online	16-Dec-2022	1-Jun-2023	NA	NA	(95:5) In <i>Chromatographic system/Spray reagent</i> : Change 0.2 g of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5) to: 2 mg/mL of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5)
LINEZOLID TABLETS	IM PURITIES/Organic Impurities	USPNF Online	Online	26-May-2023	1-Jun-2023	NA	NA	In <i>Sensitivity solution</i> : Change 0.5 ug/mL of USP Linezolid RS from <i>Standard solution in Diluent</i> to: 0.5 ?g/mL of USP Linezolid

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LINEZOLID TABLETS	PERFORMANC E TESTS	USPNF Online	26-Jan-2024	1-Feb-2024	NA	NA	<p>RS from <i>Standard solution in Diluent In Dissolution</i> ?711?/Test 1/Analysis: Change Result = $(r_U/r_S) \times C_S \times V \times (1/L) \times 100$ r_U = peak response of linezolid from the <i>Sample solution</i> r_S = peak response of linezolid from the <i>Standard solution</i> C_S = concentration of USP Linezolid RS in the <i>Standard solution</i> (mg/mL) V = volume of <i>Medium</i>, 900 mL</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<p>L = label claim (mg/Tablet) to: Result = (r_U/r_S) $\times C_S \times V \times (1/L)$ $\times D \times 100$ r_U = peak response of linezolid from the <i>Sample solution</i> r_S = peak response of linezolid from the <i>Standard solution</i> C_S = concentration of USP Linezolid RS in the <i>Standard solution</i> (mg/mL) V = volume of <i>Medium</i>, 900 mL L = label claim (mg/Tablet) D = dilution factor of the <i>Sample</i></p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LIDOCAINE, R ACEPINEPHRI NE AND TETRACAINE HYDROCHLOR IDES COMPOU NDED TOPICAL GEL	USPNF Online	Online	29-Mar-2024	1-Apr-2024	NA	NA	<p><i>solution, as needed</i></p> <p>Change Prepare Lidocaine, Racepinephrine, and Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see <i>Pharmaceutical Compounding—Sterile Preparations</i> <797>).</p> <p>to: Prepare Lidocaine, Racepinephrine, and</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LIDOCAINE HY DROCHLORID E AND DEXTROSE INJECTION	Assay for <i>lidocaine</i> <i>hydrochloride</i> <i>USPNF Online</i>	Online	24-Feb-2023	1-Mar-2023	NA	NA	Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see <i>Pharmaceutical Compounding—Nonsterile Preparations</i> <795>). Change Proceed with Injection as directed in the <i>Assay for lidocaine hydrochloride under Lidocaine and Epinephrine Injection.</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Proceed with Injection as directed in the <i>Assay for lidocaine hydrochloride under Lidocaine Hydrochloride and Epinephrine Injection.</i>
LIDOCAINE	ASSAY	USPNF Online	Online	29-Mar-2024	1-Apr-2024	NA	NA	In Procedure: Change Column: 3.9-mm x 30-cm; 4- μ m packing L1 to: Column: 3.9-mm x 30-cm; 10- μ m packing L1
LEVORPHANO L TARTRATE TABLETS	PERFORMANC E TESTS/ <i>Uniformity of Dosage Units</i> ?905?	USPNF Online	Online	31-Mar-2023	1-Aug-2023	NA	NA	In <i>Sample solution:</i> Change Nominally about 80 ug/mL of levorphanol tartrate in

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LATANOPROS ASSAY/ T Procedure	USPNF Online	Online	29-Jul-2022	1-Dec-2022	NA	NA	<p><i>Diluent</i> prepared as follows. to: Nominally about 80 µg/mL of levorphanol tartrate in <i>Diluent</i> prepared as follows. Change Standard solution: Transfer 2.0 mg/mL of USP Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chromatographic hexane to volume. Sample solution</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<p>: Transfer 2.0 mg/mL of Latanoprost into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chromatographic hexane to volume.</p> <p>to:</p> <p>Standard solution: 2.0 mg/mL of USP Latanoprost RS prepared as follows.</p> <p>Transfer USP Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LANSOPRAZO IM LE DELAYED- PUR RELEASE ITIES/ <i>Organic</i> CAPSULES <i>Impurities</i>	USPNF Online	Online	30-Sep-2022	1-Oct-2022	NA	NA	<p>20% of the final volume, and dilute with chromatographic hexane to volume.</p> <p>Sample solution: 2.0 mg/mL of Latanoprost prepared as follows. Transfer Latanoprost into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chromatographic hexane to volume.</p> <p>Delete Blank: Methanol and <i>Diluent</i> (1:9)</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOSORBIDE MONONITRAT E TABLETS	USPNF Online	Online	26-Apr-2024	1-May-2024	NA	NA	In <i>Organic Impurities/Standard solution:</i> Change isosorbide related compound A to: isosorbide mononitrate related compound A AND In <i>System suitability/Suitability requirements/Relative standard deviation:</i> Change isosorbide related compound A, to: isosorbide mononitrate related compound A, AND In four

Monograph Title	Section	Source	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOFLURANE	IM PUR ITIES/ <i>Organic Impurities</i>	USPNF Online	Online	28-Apr-2023	1-May-2023	NA	NA	instances in <i>Analysis:</i> Change isosorbide related compound A, to: isosorbide mon onitrate related compound A, AND In <i>Table 1:</i> Change Isosorbide related compound A to: Isosorbide mon onitrate related compound A In <i>Analysis:</i> Change Result = (r_U/r_S) $\times C_S \times (1/F)$ to: Result = (r_U/r_S) $\times C_F \times (1/F)$ AND Change C_S = final concentration of

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description	
ISOBUTYL ALCOHOL	ASSAY/ Procedure	USPNF Online	Online	27-Jan-2023	1-Feb-2023	NA	NA	<p>USP Isoflurane Related Compound B RS in the <i>Standard solution</i> (%) to: C_F = final concentration of USP Isoflurane Related Compound B RS in the <i>Standard solution</i> (%)</p> <p>In <i>Analysis</i>: Change r_S = sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the <i>Reference solution</i> to: r_T = sum of all the peaks</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IODIXANOL INJECTION	ADDITIONAL R EQUIREMENT S	<i>USPNF Online</i> Online	23-Feb-2024	1-Mar-2024	NA	NA	<p>carbonyl]amino] -2-hydroxypropy l]oxy]-2-hydroxy propyl](acetyla mino)]-N,N '-bis(2,3-dihydro xypropyl)-2,4,6-t riiodo-1,3-benze ndicarboxamide</p> <p>. In <i>USP</i> <i>Reference</i> <i>Standards</i> ?11?/USP Iodixanol Related Compound E RS: Change 5-[[3-[[3-[[[(2,3-D ihydroxypropyl) amino]carbonyl] -5- [[amino]carb onyl]-2,4,6-triiod ophenyl](acetyli mino)]-2-hydrox ypropyl]-(acetyli mino)]-N,N?-bis (2,3-dihydroxypr opyl)-2,4,6-triiod o-1,3-benzenedi carboxamide.</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GLYCYL-L-TYROSINE	IMPURITIES/ <i>Related Compounds</i>	USPNF Online Online	24-Feb-2023	1-Jun-2023	NA	NA	<p>to: 5-{N-[3-(N-{3-Carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-N¹,N³-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide.</p> <p>In <i>Buffer solution</i>: Change Dissolve 6.84 g of potassium phosphate in 1000 mL of water.</p> <p>to: Dissolve 6.84 g of monobasic potassium phosphate in 1000 mL of water.</p>
GLUCAGON	PROCESS-RELATED	USPNF Online Online	29-Dec-2023	1-Jan-2024	NA	NA	<p>In <i>Acetic Acid in Peptid</i></p>

Monograph Title	Section	Source	Page Number	Errata Post	Errata Official	Target Errata	Target Online	Description
Sort		Publication		Date	Date	Print Publication	Fix Publication	
ascending								
								<p>es/<i>Analysis:</i> Change C_{SPA} = concentration of potassium acetate in each of the <i>Standard</i> <i>solutions</i> (mg/mL) to: C_{SPA} = concentration of potassium acetate in each of the <i>Standard</i> <i>solutions</i> (μg/mL) AND In <i>Am</i> <i>monium/</i> <i>Analysis:</i> Change C_{SAC} = concentration of ammonium chloride in each of the <i>Standard</i> <i>solutions</i> (mg/mL) to:</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOSAMPRENA PERFORMANC VIR CALCIUM E TESTS TABLETS	USPNF Online	Online	25-Aug-2023	1-Sep-2023	NA	NA	<p>C_{SAC} = concentration of ammonium chloride in each of the <i>Standard solutions</i> ($\mu\text{g/mL}$)</p> <p>In <i>Dissolution</i> ?711?/Medium: Change 26.7 g/L of sodium acetate trihydrate in water. Add 133 mL of glacial acetic acid to this solution, and then dilute with water to 10 L; 900 mL.</p> <p>to: 0.02 M sodium acetate buffer, pH 3.5, prepared as follows. Dissolve 2.67 g of sodium acetate in 100 mL of water. Add 13.3 mL of</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUVOXAMINE ASSAY/ MALEATE <i>Procedure</i> TABLETS	<i>USPNF Online</i> Online		28-Apr-2023	1-May-2023	NA	NA	glacial acetic acid and then dilute with water to 1000 mL; 900 mL. In <i>Solution A</i> : Change 8 g/L of 1-penta nesulfonic acid sodium salt and 1 g/L of monobasic potassium phosphate in water. to: 8 g/L of 1-penta nesulfonic acid sodium salt and 1.1 g/L of monobasic potassium phosphate in water.
FLUTICASONE IM PROPIONATE PUR NASAL SPRAY ITIES/ <i>Organic</i> <i>Impurities</i>	<i>USPNF Online</i> Online		27-Jan-2023	1-Feb-2023	NA	NA	In <i>Analysis</i> : Change Samples: <i>System suitability solution, Identification</i>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUTICASONE OTHER COMP PROPIONATE ONE NASAL SPRAY NTS/ <i>Content of</i> <i>Phenylethyl</i> <i>Alcohol</i>	USPNF Online	Online	28-Apr-2023	1-May-2023	NA	NA	<i>solution, and</i> <i>Sample solution</i> to: Samples: <i>Identification</i> <i>solution and</i> <i>Sample solution</i> In <i>Sample</i> <i>solution:</i> Change Transfer 1.0 g of the Nasal Spray to a 50-mL volumetric flask. Add about 40 mL of <i>Diluent</i> , and sonicate for 10 min until the supernatant is clear. Use the clear supernatant for analysis. to: Transfer 1.0 g of the Nasal Spray to a 50-mL volumetric flask. Add about 40

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLURAZEPAM USP HYDROCHLOR REFERENCE IDE STANDARDS ?11?	USPNF Online	Online	23-Feb-2024	1-Mar-2024	NA	NA	mL of <i>Diluent</i> , and sonicate for 10 min. Dilute with <i>Diluent</i> to volume, and shake. Allow to stand for 10 min until the supernatant is clear. Use the clear supernatant for analysis. In USP Flurazepam Related Compound C RS: Change 5-Chloro-2-(2-diethylaminoethyl (amino)-2?-fluorobenzophenone hydrochloride. to: 5-Chloro-2-(2-diethylaminoethyl amino)-2?-fluorobenzophenone hydrochloride. Change Buffer, Mobile
FELODIPINE IM PUR	USPNF Online	Online	18-Nov-2022	1-Dec-2022	NA	NA	Change Buffer, Mobile

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ITIES/ <i>Organic Impurities</i>						<p>phase, System suitability solution, Standard solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay.</p> <p>to:</p> <p>Buffer, Mobile phase, System suitability solution, Standard solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay, and use 40 µL injection volume for the <i>Sensitivity solution</i>.</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EXENATIDE INJECTION	PRODUCT- RELATED SUBSTANCES AND IMPURITIES	USPNF Online Online	26-Jul-2024	1-Aug-2024	NA	NA	In Proce dure/ Chromatographi c system/Column: Change 4.6-mm x 10-cm; 3-µm packing L52 to: 4.6-mm x 10-cm; 3-µm packing L52; two columns in series
ESCITALOPRA ASSAY/ M TABLETS	Procedure	USPNF Online Online	28-Apr-2023	1-May-2023	NA	NA	In Buffer: Change Adjust with 1 N sodium hydroxide VS to a pH of 5.2. to: Adjust with 1 N sodium hydroxide to a pH of 5.2.
ESCITALOPRA PERFORMANC M TABLETS	E TESTS/ Dissolution	USPNF Online Online	28-Apr-2023	1-May-2023	NA	NA	In Test 1/Medium: Change 0.1 N

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
?711?							hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL AND <i>In Test</i> <i>2/Medium:</i> Change 0.1 N hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL
ERYTHROMYCIN IDENTIFICATION TEST UNDER ERYTHROMYCIN ETHYLSUCCINATE FOR ORAL SUSPENSION	USP Online	Online	31-Mar-2023	1-Apr-2023	NA	NA	Change Proceed as directed in the <i>Identification</i> test under <i>Erythromycin Ethylsuccinate Oral Suspension</i> , beginning with "Prepare a Standard"

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<p>solution.” to: Prepare a Standard solution of USP Erythromycin Ethylsuccinate RS in methanol containing about 3 mg per mL. Apply separately 10 µL each of the test solution and the Standard solution to a suitable thin- layer chromatog raphic plate (see <i>Chromatograph y ?621?</i>) coated with a 0.25-mm layer of chromat ographic silica gel mixture, and allow to dry. Place the plate in an unlined ch romatographic</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<p>chamber, and develop the chromatograms in a solvent system consisting of a mixture of methanol and chloroform (85:15) until the solvent front has moved about 9 cm. Remove the plate from the chamber, mark the solvent front, and allow the solvent to evaporate. Spray the plate with a mixture of dehydrated alcohol, <i>p</i>-methoxybenzaldehyde, and sulfuric acid (90:5:5). Heat the plate at 100° for 10 minutes, and</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ERYTHROMYC Assay IN ETHYLSUC CINATE FOR ORAL SUSPENSION	USPNF Online	Online	31-Mar-2023	1-Apr-2023	NA	NA	examine the chromatograms, in which the erythromycin and succinic acid moieties appear as black-to-purple spots: the R_F values of the principal spots obtained from the test solution correspond to those obtained from the Standard solution. Change Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed in the Assay under <i>Erythromycin Ethylsuccinate</i>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<p><i>Oral Suspension.</i></p> <p>to:</p> <p>Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed for erythromycin under <i>Antibiotics—Microbial Assays</i> ?81?, using an accurately measured volume of the reconstituted suspension, freshly mixed and free from air bubbles, blended for 4 ± 1 minutes in a high-speed glass blender jar with sufficient</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ERYTHROMYCIN PERFORMANC IN DELAYED- RELEASE TABLETS	USP <i>NF Online</i> Online		31-Mar-2023	1-Apr-2023	NA	NA	methanol to give a stock solution containing the equivalent of about 1 mg of erythromycin per mL. Dilute this stock solution quantitatively with <i>Buffer B.3</i> to obtain a <i>Test Dilution</i> having a concentration assumed to be equal to the median dose level of the Standard. In <i>Test 1</i> : Change Buffer stage Medium: 0.05 M pH 6.8 phosphate buffer (see <i>Reagents, Indicators, and Solutions—Buffer</i>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ENZACAMENE ASSAY/ Procedure	USPNF Online	Online	28-Oct-2022	1-Dec-2022	NA	NA	<p><i>r Solutions</i>) to: Buffer stage Medium: 0.05 M pH 6.8 phosphate buffer (see <i>Reagents,</i> <i>Indicators, and</i> <i>Solutions—Buffe</i> <i>r Solutions</i>); 900 mL In <i>Analysis</i>: Change $C_U =$ concentration of enzacamene in the <i>Sample</i> <i>solution</i> (mg/mL) to: $C_U =$ concentration of Enzacamene in the <i>Sample</i> <i>solution</i> (mg/mL)</p>
ENSULIZOLE IDENTIFICATION	USPNF Online	Online	29-Mar-2024	1-Apr-2024	NA	NA	<p>In <i>B.</i>: Change The retention time of the</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EDETATE DISODIUM CO MPOUNDED OPHTHALMIC SOLUTION	DEFINITION <i>USPNF Online</i>	Online	28-Jun-2024	1-Jul-2024	NA	NA	<p>major peak of the <i>Sample solution</i> exhibits maxima and minima at the same wavelengths as those of the <i>Standard solution</i>, as obtained in the Assay.</p> <p>to: The retention time of the major peak of the <i>Sample solution</i> corresponds to that of the <i>Standard solution</i>, as obtained in the Assay.</p> <p>In two instances: Change to a pH between 6.5 and 7.5.</p> <p>to:</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DUTASTERIDE PERFORMANCE AND TAMSULOSIN HYDROCHLORIDE CAPSULES	USPNF Online	Online	17-Nov-2023	1-Dec-2023	NA	NA	to a pH between 6.1 and 7.1. In <i>Dissolution</i> ?711?/Test for <i>dutasteride</i> /Tier 2/Medium: Change 10 g/L of cetyltrimethylammonium bromide and 750,000 USP units of activity/mg of pepsin, purified in 0.1 N hydrochloric acid; 900 mL to: Dissolve 10 g of cetyltrimethylammonium bromide and 1.6 g of pepsin, purified in 1000 mL of 0.1 N hydrochloric acid; 900 mL
DUTASTERIDE ADDITIONAL REQUIREMENTS AND TAMSULOSIN S	USPNF Online	Online	17-Nov-2023	1-Dec-2023	NA	NA	In <i>USP Reference Standards</i>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLOR IDE CAPSULES							?11?/USP Dihydrodutasteride RS: Change <i>N</i> -[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androst-1-ene-17?-carboxamide. to: <i>N</i> -[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androstane-17?-carboxamide.
DOXORUBICIN ASSAY/ HYDROCHLOR IDE INJECTION	<i>USPNF Online</i> Online		28-Oct-2022	1-Nov-2022	NA	NA	In <i>Analysis</i> : Change <i>P</i> = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: <i>P</i> = potency of doxorubicin hydrochloride in USP Doxorubicin

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXORUBICIN IM HYDROCHLOR PUR IDE INJECTIONITIES/ <i>Organic</i> <i>Impurities</i>	<i>USPNF 2022</i> <i>Online</i>	Online	28-Oct-2022	1-Nov-2022	NA	NA	Hydrochloride RS (µg/mg) In <i>Analysis</i> : Change <i>P</i> = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: <i>P</i> = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) In <i>Analysis</i> : Change <i>P</i> = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: <i>P</i> = potency of doxorubicin hydrochloride in USP
DOXORUBICIN ASSAY/ HYDROCHLOR <i>Procedure</i> IDE FOR INJECTION	<i>USPNF Online</i> <i>Online</i>	Online	28-Oct-2022	1-Nov-2022	NA	NA	Hydrochloride RS (µg/mg) In <i>Analysis</i> : Change <i>P</i> = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: <i>P</i> = potency of doxorubicin hydrochloride in USP

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXORUBICIN IM HYDROCHLOR PUR IDE FOR INJECTION	ITIES/ <i>Organic</i> <i>Impurities</i>	USPNF Online Online	28-Oct-2022	1-Nov-2022	NA	NA	Doxorubicin Hydrochloride RS (µg/mg) In <i>Analysis</i> : Change <i>P</i> = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: <i>P</i> = potency of doxorubicin hydrochloride in USP
DOXORUBICIN ASSAY HYDROCHLOR IDE		USPNF Online Online	26-Apr-2024	1-May-2024	NA	NA	Doxorubicin Hydrochloride RS (µg/mg) In <i>Procedure/System suitability solution</i> : Add link to USP Store for USP Epirubicin Hydrochloride RS
DOXAZOSIN MESYLATE	IM PUR	USPNF Online Online	28-Oct-2022	1-Nov-2022	NA	NA	In <i>Analysis</i> : Change

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ITIES/ <i>Organic Impurities</i>							$C_S =$ concentration of the corresponding USP Doxazosin Related Compound RS or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the <i>Standard</i> <i>solution</i> (mg/mL) to: $C_S =$ concentration of the corresponding USP Reference Standard or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the <i>Standard</i> <i>solution</i> (mg/mL)

Monograph Title	Section	Source	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOFETILIDE	CHEMICAL INFORMATION	<i>USPNF Online</i>	Online	28-Oct-2022	1-Nov-2022	NA	NA	Change ?-[<i>p</i> -Methanesulfonamidophenethyl)methylamino]methane sulfono- <i>p</i> -phenetidide to: <i>N</i> -[4-[2-(Methyl{2-[4-(methylsulfonamido)phenoxy]ethyl}amino)ethyl]phenyl]methanesulfonamide
DOCETAXEL	IMPURITIES	<i>USPNF Online</i>	Online	31-May-2024	1-Jun-2024	NA	NA	In <i>Organic Impurities, Procedure 1:</i> Change System suitability solution, Standard solution, Sample solution, and Chromatographic system: Proceed as directed in the

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIVALPROEX PERFORMANC SODIUM EXTE E TESTS NDED- RELEASE TABLETS	<i>USPNF Online</i> Online		29-Sep-2023	1-Oct-2023	NA	NA	Assay. to: Mobile phase, Diluent, System suitability solution, Standard solution, Sample solution, and Chromatograp hic system: Proceed as directed in the <i>Assay.</i> In <i>Dissolution</i> ?711?/ <i>Test</i> <i>8/Tolerances:</i> Change The percentage of the labeled amount of valproic acid (C ₈ H ₁₆ O ₂) dissolved at the times specified conform to <i>Dissolution</i> <711>, <i>Acceptance</i>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DILUTED ISOSORBIDE MONONITRAT E	IMPURITIES <i>USPNF Online</i>	Online	26-Apr-2024	1-May-2024	NA	NA	<p><i>Table 1.</i> to: The percentage of the labeled amount of valproic acid (C₈H₁₆O₂) dissolved at the times specified conform to <i>Dissolution <711></i>, <i>Acceptance Table 2.</i></p> <p>In <i>Organic Impurities/Standard solution</i>: Change isosorbide related compound A to: isosorbide mononitrate related compound A AND In <i>System suitability/Suitability</i> <i>re</i></p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<p><i>quire</i> <i>ments/Relative</i> <i>standard</i> <i>deviation:</i> Change isosorbide related compound A, to: isosorbide mon onitrate related compound A, AND In four instances in <i>Analysis:</i> Change isosorbide related compound A, to: isosorbide mon onitrate related compound A, AND In <i>Table 1:</i> Change Isosorbide related compound A to:</p>

Monograph Title Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description	
DILTIAZEM HY IDENTIFICATIO DROCHLORID N E EXTENDED- RELEASE CAPSULES	USPNF Online	Online	28-Apr-2023	1-May-2023	NA	NA	Isosorbide mononitrate related compound A Change A. The UV-Vis spectrum of the major peak of the <i>Sample solution</i> corresponds to that of the <i>Standard solution</i> , as obtained in the Assay. to: A. The UV spectrum of the major peak of the <i>Sample solution</i> corresponds to that of the <i>Standard solution</i> , as obtained in the Assay.	
DIGOXIN TABLETS	ASSAY	USPNF Online	Online	29-Sep-2023	1-Oct-2023	NA	NA	In <i>Procedure/Analysis:</i>

Monograph Title	Section	Source	Page Number	Errata Post	Errata Official	Target Errata	Target Online	Description
Sort		Publication		Date	Date	Print Publication	Fix Publication	
ascending								
								Change C_U = nominal concentration of in the <i>Sample solution</i> ($\mu\text{g/mL}$) to: C_U = nominal concentration of digoxin in the <i>Sample solution</i> ($\mu\text{g/mL}$)

Pagination

- [First page « First](#)
- [Previous page ‹ Previous](#)
- [Page 1](#)
- [Page 2](#)
- [Current page 3](#)
- [Page 4](#)
- [Page 5](#)
- [Next page Next ›](#)
- [Last page Last »](#)